ALX Oncology (NASDAQ:ALXO) Hits New 52-Week High at $17.45

ALX Oncology Holdings Inc. (NASDAQ:ALXO) reached a new 52-week high during mid-day trading on Monday . The company traded as high as $17.45 and last traded at $17.32, with a volume of 247131 shares trading hands. The stock had previously closed at $16.86.

Analysts Set New Price Targets

A number of analysts have issued reports on ALXO shares. Stifel Nicolaus reiterated a “hold” rating and issued a $14.00 target price (up from $10.00) on shares of ALX Oncology in a research note on Friday, March 8th. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of ALX Oncology in a research note on Wednesday, April 10th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of ALX Oncology in a research note on Friday, April 12th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, ALX Oncology presently has a consensus rating of “Moderate Buy” and an average target price of $18.83.

ALX Oncology Stock Performance

The stock’s 50-day moving average is $13.63 and its 200-day moving average is $12.31. The company has a debt-to-equity ratio of 0.05, a quick ratio of 5.24 and a current ratio of 5.24.

ALX Oncology (NASDAQ:ALXO) last announced its earnings results on Thursday, March 7th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.09). Analysts predict that ALX Oncology Holdings Inc. will post -3.33 EPS for the current year.

Insider Buying and Selling

In other news, insider Jaume Pons sold 50,000 shares of the business’s stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $14.20, for a total value of $710,000.00. Following the completion of the sale, the insider now owns 604,205 shares of the company’s stock, valued at $8,579,711. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, CEO Jason Lettmann bought 4,400 shares of ALX Oncology stock in a transaction that occurred on Thursday, March 14th. The shares were acquired at an average cost of $11.31 per share, for a total transaction of $49,764.00. Following the completion of the acquisition, the chief executive officer now directly owns 171,620 shares of the company’s stock, valued at approximately $1,941,022.20. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jaume Pons sold 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, April 16th. The stock was sold at an average price of $14.20, for a total value of $710,000.00. Following the transaction, the insider now directly owns 604,205 shares in the company, valued at $8,579,711. The disclosure for this sale can be found here. 50.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On ALX Oncology

A number of institutional investors and hedge funds have recently bought and sold shares of ALXO. SG Americas Securities LLC purchased a new stake in ALX Oncology in the 3rd quarter valued at $48,000. Barclays PLC increased its position in shares of ALX Oncology by 57.1% during the 3rd quarter. Barclays PLC now owns 26,964 shares of the company’s stock valued at $129,000 after purchasing an additional 9,796 shares during the last quarter. Forefront Analytics LLC purchased a new stake in shares of ALX Oncology during the 3rd quarter valued at $66,000. J.P. Morgan Private Wealth Advisors LLC purchased a new stake in shares of ALX Oncology during the 3rd quarter valued at $96,000. Finally, Hsbc Holdings PLC purchased a new stake in shares of ALX Oncology during the 3rd quarter valued at $168,000. 97.97% of the stock is owned by hedge funds and other institutional investors.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.